Scarica l'app Stockscreener
25.80
0.26%
0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DOCS Giù?
Forum
Previsione
Precedente Chiudi:
$25.77
Aprire:
$25.7
Volume 24 ore:
1.44M
Relative Volume:
0.40
Capitalizzazione di mercato:
$4.77B
Reddito:
$637.78M
Utile/perdita netta:
$239.40M
Rapporto P/E:
21.66
EPS:
1.1909
Flusso di cassa netto:
$307.21M
1 W Prestazione:
+6.76%
1M Prestazione:
+12.04%
6M Prestazione:
-58.71%
1 anno Prestazione:
-54.75%
Intervallo 1D:
$24.80
$25.86
Intervallo di 1 settimana:
$23.40
$25.86
Portata 52W:
$20.55
$76.51
Doximity Inc Stock (DOCS) Company Profile
Nome
Doximity Inc
Settore
Industria
Telefono
(650) 549-4330
Indirizzo
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, TEM, HQY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
25.82 | 4.76B | 637.78M | 239.40M | 307.21M | 1.1909 |
VEEV
Veeva Systems Inc
|
169.01 | 27.94B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
52.61 | 9.98B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
53.45 | 9.70B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
83.61 | 6.98B | 1.31B | 215.20M | 408.32M | 2.4627 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Downgrade | Truist | Buy → Hold |
| 2026-04-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2026-02-09 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-01-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Iniziato | BMO Capital Markets | Market Perform |
| 2025-10-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Downgrade | Goldman | Neutral → Sell |
| 2025-07-09 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-02-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Iniziato | Stephens | Equal-Weight |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-11-15 | Iniziato | Goldman | Neutral |
| 2024-11-14 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Aggiornamento | Needham | Hold → Buy |
| 2024-07-18 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2024-01-02 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-08-09 | Downgrade | Needham | Buy → Hold |
| 2023-08-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Iniziato | Wells Fargo | Overweight |
| 2022-10-24 | Iniziato | Evercore ISI | In-line |
| 2022-10-13 | Iniziato | BTIG Research | Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Iniziato | Berenberg | Buy |
| 2022-05-18 | Reiterato | BofA Securities | Neutral |
| 2022-05-18 | Reiterato | Goldman | Buy |
| 2022-05-18 | Reiterato | Guggenheim | Buy |
| 2022-05-18 | Reiterato | Jefferies | Buy |
| 2022-05-18 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Reiterato | Needham | Buy |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-04 | Iniziato | BofA Securities | Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2021-12-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-10 | Reiterato | Canaccord Genuity | Buy |
| 2021-11-10 | Reiterato | Goldman | Neutral |
| 2021-11-10 | Reiterato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Reiterato | Needham | Buy |
| 2021-11-10 | Reiterato | Piper Sandler | Overweight |
| 2021-08-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-19 | Iniziato | Goldman | Neutral |
| 2021-07-19 | Iniziato | JP Morgan | Overweight |
| 2021-07-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Iniziato | Piper Sandler | Overweight |
| 2021-07-19 | Iniziato | Raymond James | Outperform |
| 2021-07-19 | Iniziato | SVB Leerink | Outperform |
| 2021-07-19 | Iniziato | William Blair | Outperform |
Mostra tutto
Doximity Inc Borsa (DOCS) Ultime notizie
Doximity (DOCS) price target decreased by 31.04% to 44.25 - MSN
Harel Insurance Investments & Financial Services Ltd. Purchases 90,341 Shares of Doximity, Inc. $DOCS - MarketBeat
Vanguard Group Inc. Buys 518,916 Shares of Doximity, Inc. $DOCS - MarketBeat
Zacks Industry Outlook Highlights Veeva Systems, Doximity and Omnicell - Yahoo Finance
Is Doximity, Inc. (DOCS) A Good Stock To Buy Now? - Insider Monkey
Is Doximity (DOCS) a Good Stock to Buy? Bullish Thesis Breakdown - HarianBasis.co
Doximity earnings up next: Can guidance ease valuation pressure? By Investing.com - Investing.com Nigeria
Move Over Doximity — There’s a New Social Network for Doctors - MedCity News
Paul Jorgensen of Doximity Pleads Guilty in $2.5M Insider Trading Case - hannahhowell.com
Assessing Doximity (DOCS) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan Small Cap Equity Fund's Doximity Inc(DOCS) Holding History - GuruFocus
DOCS SEC FilingsDoximity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Should Doximity’s CFO Transition Before Earnings Require Action From Doximity (DOCS) Investors? - simplywall.st
Vanguard reports 6.79M Doximity shares; Schedule 13G shows 5.07% (DOCS) - Stock Titan
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack (NYSE:DOCS) - Seeking Alpha
Doximity Stock at $25: Priced for Decline or Positioned for a Double-Digit Rebound? - TIKR.com
Is It Too Late To Consider Buying Doximity, Inc. (NYSE:DOCS)? - 富途牛牛
Doximity drops as guidance trails consensus - MSN
Doximity (DOCS) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Evercore Maintains Doximity(DOCS.US) With Hold Rating, Maintains Target Price $25 - Moomoo
Doximity, Inc. (DOCS) Stock Analysis: A Look at Its 57% Potential Upside and Strong Buy Sentiment - DirectorsTalk Interviews
Doximity CFO resigns; interim finance head continues - msn.com
Doximity CFO Exit Puts Focus On Finance Stability And Capital Choices - Sahm
Doximity reaches $31M settlement in securities litigation lawsuit - MSN
Evercore ISI Group Maintains Doximity (DOCS) Outperform Recommendation - MSN
Doximity (DOCS) stock dips while market gains: Key facts - MSN
Evercore ISI Group downgrades Doximity (DOCS) - MSN
Victory Sustainable World Fund's Doximity Inc(DOCS) Holding History - GuruFocus
Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026 - The Joplin Globe
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch By Investing.com - Investing.com India
VY(R) JPMorgan Small Cap Core Equity Portfolio's Doximity Inc(DOCS) Holding History - GuruFocus
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch - Investing.com Australia
Wall Street Analysts Think Doximity (DOCS) Is a Good Investment: Is It? - Yahoo Finance
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine? - TradingView
Doximity (NYSE:DOCS) Stock Rating Upgraded by Zacks Research - MarketBeat
Is Doximity (DOCS) stock stable under market conditions | Doximity posts 1.2% EPS beat, solid Q1 revenueBest Pick - Xã Thanh Hà
DOCS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform - TradingView
Truist Securities downgrades Doximity (DOCS) - MSN
Doximity (DOCS) falls more steeply than broader market: What investors need to know - MSN
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
BofA Cuts PT on Doximity, Inc. (DOCS) to $47 From $56 - Insider Monkey
Doximity (NYSE:DOCS) Shares Gap DownTime to Sell? - MarketBeat
Doximity stock holds Strong Buy at Raymond James after CFO exit By Investing.com - Investing.com South Africa
Doximity stock holds Strong Buy at Raymond James after CFO exit - Investing.com Australia
Leerink raises Doximity stock price target to $34 on valuation By Investing.com - Investing.com South Africa
Doximity (DOCS) Faces Downgrade and Adjusted Growth Outlook - GuruFocus
Leerink raises Doximity stock price target to $34 on valuation - Investing.com UK
Doximity Inc Azioni (DOCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.12%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):